News
4dOpinion
MedPage Today on MSNHow Fast Is Too Fast for FDA Drug Review?In announcing his new Commissioner's National Priority Voucher (CNPV) program, FDA Commissioner Marty Makary, MD, MPH, ...
Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway ...
While there's little disagreement that speeding drug approvals would be a good thing, there are more questions than answers ...
FDA Commissioner Marty Makary’s pledge to reexamine the safety of medication abortion isn’t just pointless — it’s dangerous.
Makary and Center for Biologics Evaluation and Research Director Vinay Prasad unveiled a new framework in the New England ...
Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots ...
But current and former agency staff, as well as medical ethics experts, say recent cuts at the FDA are already making it more ...
Mike Davis previously worked as clinical team leader at the FDA’s Division of Psychiatry before serving as chief medical ...
FDA Commissioner Marty Makary reportedly initiated a brief request last week to decline approval of a rare disease drug ...
Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...
Novo Nordisk is halting its collaboration with Hims & Hers Health over the sale of weight loss drugs, STAT says. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results